The UK company is the latest to join ranks of AI-focused drugmakers attracting venture capital.

The researcher who invented Viagra and a colleague at Cambridge University have become the latest to join the ranks of drug developers using artificial intelligence and attracting attention from venture capitalists.

Cambridge, UK-based Healx said Thursday that it had raised $10 million in a Series A funding round, led by London-based venture capital firm Balderton Capital. Fellow British venture capital firm Amadeus Capital Partners and Jonathan Milner – founder of life sciences supplier Abcam – also participated. Cambridge Rare Diseases Network founder Tim Guilliams and David Brown – who invented Pfizer’s erectile dysfunction drug, which is now available as a generic – are the founders of Healx.

The company uses the HealNet database, which maps more than 1 billion disease, patient and drug interactions and was built and maintained using machine learning techniques. The company plans to use the Series A round to expand its team of software engineers, data scientists, pharmacologists and drug development researchers.

Image Credit:  Alias Studio Sydney

News This Week

Novel Investment Paradigms for Regenerative Healthcare Ecosystems

Introduction The transition toward regenerative healthcare ecosystems—anchored in wellness optimization, disease prevention, eradication strategies, and healthy longevity—necessitates a structural reconfiguration of capital architectures, governance models, and incentive design. Regenerative healthcare, by definition, transcends episodic [...]

Our books now available worldwide!

Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]